Should I buy or sell UroGen Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" URGN shares. View URGN analyst ratings or view top-rated stocks .

What is UroGen Pharma's stock price target for 2024?

3 Wall Street research analysts have issued 1 year target prices for UroGen Pharma's stock. Their URGN share price targets range from $10.00 to $54.00. On average, they anticipate the company's stock price to reach $37.00 in the next year. This suggests a possible upside of 162.4% from the stock's current price. View analysts price targets for URGN or view top-rated stocks among Wall Street analysts .

How have URGN shares performed in 2023?

UroGen Pharma's stock was trading at $8.87 at the beginning of the year. Since then, URGN shares have increased by 59.0% and is now trading at $14.10. View the best growth stocks for 2023 here .

Are investors shorting UroGen Pharma?

UroGen Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,830,000 shares, an increase of 23.6% from the October 31st total of 2,290,000 shares. Based on an average daily volume of 248,800 shares, the days-to-cover ratio is currently 11.4 days. View UroGen Pharma's Short Interest .

When is UroGen Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our URGN earnings forecast .

How were UroGen Pharma's earnings last quarter?

UroGen Pharma Ltd. (NASDAQ:URGN) announced its earnings results on Tuesday, November, 14th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.21. The firm earned $20.85 million during the quarter, compared to analysts' expectations of $19.80 million.

What ETF holds UroGen Pharma's stock ?

ARK Israel Innovative Technology ETF holds 218,434 shares of URGN stock, representing 1.96% of its portfolio.

What other stocks do shareholders of UroGen Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE) , Micron Technology (MU) , OPKO Health (OPK) , TG Therapeutics (TGTX) , VBI Vaccines (VBIV) , Exelixis (EXEL) , (KITE) (KITE) , Syndax Pharmaceuticals (SNDX) , AbbVie (ABBV) and Aytu BioPharma (AYTU) .

When did UroGen Pharma IPO?

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

Who are UroGen Pharma's major shareholders?

UroGen Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (6.33%), Harel Insurance Investments & Financial Services Ltd. (3.71%), Migdal Insurance & Financial Holdings Ltd. (2.76%), Silverarc Capital Management LLC (2.17%), Laurion Capital Management LP (1.62%) and Clal Insurance Enterprises Holdings Ltd (0.95%). Insiders that own company stock include Elizabeth A Barrett , Jason Drew Smith , Mark Schoenberg and Molly Henderson . View institutional ownership trends .

How do I buy shares of UroGen Pharma?

Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

UroGen Pharma (URGN) Stock Price, News & Analysis

$14.10

-0.17 (-1.19%)

(As of 10:39 AM ET)

Compare

Today's Range: $13.93
▼
$14.35
50-Day Range: $10.87
▼
$14.44
52-Week Range: $7.15
▼
$24.13

Volume: 34,610 shs
Average Volume: 310,370 shs
Market Capitalization: $330.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.00

UroGen Pharma MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 162.4% Upside
$37.00 Price Target
Short Interest: Bearish
12.07% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.33
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.54) to ($2.61) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

657th out of 942 stocks

Pharmaceutical Preparations Industry

304th out of 424 stocks

3.3

Analyst's Opinion

Consensus Rating
UroGen Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.00, UroGen Pharma has a forecasted upside of 162.4% from its current price of $14.10.
Amount of Analyst Coverage
UroGen Pharma has only been the subject of 2 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
12.07% of the outstanding shares of UroGen Pharma have been sold short.
Short Interest Ratio / Days to Cover
UroGen Pharma has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.
Change versus previous month
Short interest in UroGen Pharma has recently increased by 23.58%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
UroGen Pharma does not currently pay a dividend.
Dividend Growth
UroGen Pharma does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
UroGen Pharma has received a 70.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other cancer medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for UroGen Pharma is -1.33.

0.6

News and Social Media Coverage

MarketBeat Follows
2 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, UroGen Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.13% of the stock of UroGen Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
63.42% of the stock of UroGen Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for UroGen Pharma are expected to grow in the coming year, from ($3.54) to ($2.61) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of UroGen Pharma is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of UroGen Pharma is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About UroGen Pharma Stock (NASDAQ:URGN)

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for NMIBC. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

URGN Stock Price History

30 days | 90 days | 365 days | Advanced Chart

URGN Stock News Headlines

November 27, 2023 | finance.yahoo.com

Shareholders in UroGen Pharma (NASDAQ:URGN) are in the red if they invested five years ago

November 15, 2023 | finance.yahoo.com

UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript

December 11, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 14, 2023 | markets.businessinsider.com

UroGen Pharma Ltd. Q3 Loss decreases, beats estimates

November 14, 2023 | finance.yahoo.com

UroGen Pharma Reports Third Quarter 2023 Financial Results

November 14, 2023 | finance.yahoo.com

UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials

November 13, 2023 | benzinga.com

Preview: UroGen Pharma's Earnings

November 13, 2023 | finance.yahoo.com

UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology

December 11, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

November 12, 2023 | nasdaq.com

UroGen Pharma (FRA:UR8) Price Target Increased by 29.89% to 36.83

November 7, 2023 | finance.yahoo.com

UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023

October 30, 2023 | finance.yahoo.com

Institutional investors own a significant stake of 50% in UroGen Pharma Ltd. (NASDAQ:URGN)

October 4, 2023 | markets.businessinsider.com

Promising Clinical Progress and Profitability Prospects: An In-depth Analysis of Urogen Pharma’s UGN-102

October 4, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for UroGen Pharma

October 3, 2023 | markets.businessinsider.com

UroGen Pharma Says FDA Approves Plan For Rolling NDA Submission For UGN-102 From January 2024

August 18, 2023 | finance.yahoo.com

UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why

August 18, 2023 | fool.com

UroGen Pharma (NASDAQ: URGN)

August 17, 2023 | finance.yahoo.com

New Treatment for Bladder Cancer Offers This Biotech a Second Chance

August 12, 2023 | finance.yahoo.com

UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript

August 12, 2023 | markets.businessinsider.com

Goldman Sachs Remains a Hold on Urogen Pharma (URGN)

August 10, 2023 | markets.businessinsider.com

UroGen Pharma Ltd. Q2 Loss decreases, beats estimates

August 10, 2023 | finance.yahoo.com

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet

August 10, 2023 | finance.yahoo.com

UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments

August 8, 2023 | finance.yahoo.com

The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

August 3, 2023 | finance.yahoo.com

UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

August 2, 2023 | msn.com

HC Wainwright & Co. Maintains UroGen Pharma (URGN) Buy Recommendation

August 2, 2023 | msn.com

UroGen Pharma (URGN) Price Target Increased by 22.33% to 32.13

See More Headlines

Receive URGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/14/2023
Today: 12/11/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:URGN
CUSIP: N/A
CIK: 1668243
Web: www.urogen.com
Phone: (646) 768-9780
Fax: N/A
Employees: 192
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $37.00
High Stock Price Target: $54.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +162.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.23)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-109,780,000.00
Net Margins: -135.20%
Pretax Margin: -135.03%
Return on Equity: N/A
Return on Assets: -77.74%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.06
Quick Ratio: 6.87

Sales & Book Value

Annual Sales: $64.36 million
Price / Sales: 5.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($3.93) per share
Price / Book: -3.59

Miscellaneous

Outstanding Shares: 23,450,000
Free Float: 20,844,000
Market Cap: $330.65 million
Optionable: Optionable
Beta: 1.00

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Ms. Elizabeth A. Barrett (Age 61)
President, CEO & Director
Comp: $1.12M
Mr. Dong Kim (Age 46)
Chief Financial Officer
Comp: $546.68k
Mr. Jason Drew Smith (Age 51)
General Counsel, Chief Compliance Officer & Corporate Secretary
Comp: $717.58k
Vincent I. Perrone
Senior Director of Investor Relations
Mr. Bryon Wornson
Executive Vice President of Talent, Advocacy & Communications
Dr. Sari Prutchi-Sagiv Ph.D.
Marketing Director
Dr. Marina Konorty
Executive Vice President of Research & Development and Technical Operations
Dr. Mark P. Schoenberg M.D. (Age 65)
Chief Medical Officer
Comp: $579.5k
Mr. Jeffrey Bova M.B.A.
Chief Commercial Officer
Mr. James Ottinger R.ph.
Executive Vice President of Regulatory Affairs & Quality

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

URGN Stock Analysis - Frequently Asked Questions

Should I buy or sell UroGen Pharma stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" URGN shares.
View URGN analyst ratings or view top-rated stocks.
What is UroGen Pharma's stock price target for 2024?: 3 Wall Street research analysts have issued 1 year target prices for UroGen Pharma's stock. Their URGN share price targets range from $10.00 to $54.00. On average, they anticipate the company's stock price to reach $37.00 in the next year. This suggests a possible upside of 162.4% from the stock's current price.
View analysts price targets for URGN or view top-rated stocks among Wall Street analysts.
How have URGN shares performed in 2023?: UroGen Pharma's stock was trading at $8.87 at the beginning of the year. Since then, URGN shares have increased by 59.0% and is now trading at $14.10.
View the best growth stocks for 2023 here.
Are investors shorting UroGen Pharma?: UroGen Pharma saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,830,000 shares, an increase of 23.6% from the October 31st total of 2,290,000 shares. Based on an average daily volume of 248,800 shares, the days-to-cover ratio is currently 11.4 days.
View UroGen Pharma's Short Interest.
When is UroGen Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our URGN earnings forecast.
How were UroGen Pharma's earnings last quarter?: UroGen Pharma Ltd. (NASDAQ:URGN) announced its earnings results on Tuesday, November, 14th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.89) by $0.21. The firm earned $20.85 million during the quarter, compared to analysts' expectations of $19.80 million.

What ETF holds UroGen Pharma's stock ?: ARK Israel Innovative Technology ETF holds 218,434 shares of URGN stock, representing 1.96% of its portfolio.
What other stocks do shareholders of UroGen Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU).
When did UroGen Pharma IPO?: (URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company acted as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
Who are UroGen Pharma's major shareholders?: UroGen Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (6.33%), Harel Insurance Investments & Financial Services Ltd. (3.71%), Migdal Insurance & Financial Holdings Ltd. (2.76%), Silverarc Capital Management LLC (2.17%), Laurion Capital Management LP (1.62%) and Clal Insurance Enterprises Holdings Ltd (0.95%). Insiders that own company stock include Elizabeth A Barrett, Jason Drew Smith, Mark Schoenberg and Molly Henderson.
View institutional ownership trends.
How do I buy shares of UroGen Pharma?: Shares of URGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:URGN) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial